Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wakeling, A. E.
Right arrow Articles by Gibson, K. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wakeling, A. E.
Right arrow Articles by Gibson, K. H.
[Cancer Research 62, 5749-5754, October 15, 2002]
© 2002 American Association for Cancer Research

Experimental Therapeutics

ZD1839 (Iressa)

An Orally Active Inhibitor of Epidermal Growth Factor Signaling with Potential for Cancer Therapy

Alan E. Wakeling1, Simon P. Guy, Jim R. Woodburn, Susan E. Ashton, Brenda J. Curry, Andrew J. Barker and Keith H. Gibson

Department of Cancer and Infection Research, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom

The epidermal growth factor receptor (EGFR) is a promising target for anticancer therapy because of its role in tumor growth, metastasis and angiogenesis, and tumor resistance to chemotherapy and radiotherapy. We have developed a low-molecular-weight EGFR tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (Iressa2 ). ZD1839, a substituted anilinoquinazoline, is a potent EGFR-TKI (IC50 = 0.033 µM) that selectively inhibits EGF-stimulated tumor cell growth (IC50 = 0.054 µM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. In studies with mice bearing a range of human tumor-derived xenografts, ZD1839 given p.o. once a day inhibited tumor growth in a dose-dependent manner. The level of expression of EGFR did not determine xenograft tumor sensitivity to ZD1839. Long-term ZD1839 (>3 months) treatment of mice bearing A431 xenografts was well tolerated, and ZD1839 completely inhibited tumor growth and induced regression of established tumors. No drug-resistant tumors appeared during ZD1839 treatment, but some tumors regrew after drug withdrawal. These studies indicate the potential utility of ZD1839 in the treatment of many human tumors and indicate that continuous once-a-day p.o. dosing might be a suitable therapeutic regimen.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
W. Ren, B. Korchin, Q.-S. Zhu, C. Wei, A. Dicker, J. Heymach, A. Lazar, R. E. Pollock, and D. Lev
Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth In vitro and In vivo
Clin. Cancer Res., May 1, 2008; 14(9): 2785 - 2795.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Soeda, A. Inagaki, N. Oka, Y. Ikegame, H. Aoki, S.-i. Yoshimura, S. Nakashima, T. Kunisada, and T. Iwama
Epidermal Growth Factor Plays a Crucial Role in Mitogenic Regulation of Human Brain Tumor Stem Cells
J. Biol. Chem., April 18, 2008; 283(16): 10958 - 10966.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Dougherty, A. Sehdev, S. Cerda, R. Mustafi, N. Little, W. Yuan, S. Jagadeeswaran, A. Chumsangsri, J. Delgado, M. Tretiakova, et al.
Epidermal Growth Factor Receptor Controls Flat Dysplastic Aberrant Crypt Foci Development and Colon Cancer Progression in the Rat Azoxymethane Model
Clin. Cancer Res., April 15, 2008; 14(8): 2253 - 2262.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Okabe, I. Okamoto, S. Tsukioka, J. Uchida, T. Iwasa, T. Yoshida, E. Hatashita, Y. Yamada, T. Satoh, K. Tamura, et al.
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
Mol. Cancer Ther., March 1, 2008; 7(3): 599 - 606.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
V. Benedetti, P. Perego, G. Luca Beretta, E. Corna, S. Tinelli, S. C. Righetti, R. Leone, P. Apostoli, C. Lanzi, and F. Zunino
Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds
Mol. Cancer Ther., March 1, 2008; 7(3): 679 - 687.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Tanaka, A. Munshi, C. Brooks, J. Liu, M. L. Hobbs, and R. E. Meyn
Gefitinib Radiosensitizes Non-Small Cell Lung Cancer Cells by Suppressing Cellular DNA Repair Capacity
Clin. Cancer Res., February 15, 2008; 14(4): 1266 - 1273.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Wang, P. Guo, X. Wang, Q. Zhou, and J. M. Gallo
Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
Mol. Cancer Ther., February 1, 2008; 7(2): 407 - 417.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. L. Emanuel, T. V. Hughes, M. Adams, C. A. Rugg, A. Fuentes-Pesquera, P. J. Connolly, N. Pandey, S. Moreno-Mazza, J. Butler, V. Borowski, et al.
Cellular and in Vivo Activity of JNJ-28871063, A Nonquinazoline Pan-ErbB Kinase Inhibitor That Crosses the Blood-Brain Barrier and Displays Efficacy against Intracranial Tumors
Mol. Pharmacol., February 1, 2008; 73(2): 338 - 348.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. M. Gilmer, L. Cable, K. Alligood, D. Rusnak, G. Spehar, K. T. Gallagher, E. Woldu, H. L. Carter, A. T. Truesdale, L. Shewchuk, et al.
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
Cancer Res., January 15, 2008; 68(2): 571 - 579.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Krol, R. E. Francis, A. Albergaria, A. Sunters, A. Polychronis, R. C. Coombes, and E. W.-F. Lam
The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells
Mol. Cancer Ther., December 1, 2007; 6(12): 3169 - 3179.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Janne, J. von Pawel, R. B. Cohen, L. Crino, C. A. Butts, S. S. Olson, I. A. Eiseman, A. A. Chiappori, B. Y. Yeap, P. F. Lenehan, et al.
Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non Small-Cell Lung Cancer
J. Clin. Oncol., September 1, 2007; 25(25): 3936 - 3944.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. E. Smith, G. Walsh, A. Skene, A. Llombart, J. I. Mayordomo, S. Detre, J. Salter, E. Clark, P. Magill, and M. Dowsett
A Phase II Placebo-Controlled Trial of Neoadjuvant Anastrozole Alone or With Gefitinib in Early Breast Cancer
J. Clin. Oncol., September 1, 2007; 25(25): 3816 - 3822.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
F. Yamasaki, D. Zhang, C. Bartholomeusz, T. Sudo, G. N. Hortobagyi, K. Kurisu, and N. T. Ueno
Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
Mol. Cancer Ther., August 1, 2007; 6(8): 2168 - 2177.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Rosano, V. Di Castro, F. Spinella, G. Tortora, M. R. Nicotra, P. G. Natali, and A. Bagnato
Combined Targeting of Endothelin A Receptor and Epidermal Growth Factor Receptor in Ovarian Cancer Shows Enhanced Antitumor Activity
Cancer Res., July 1, 2007; 67(13): 6351 - 6359.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. S. Tsao, D. He, B. Saigal, S. Liu, J. J. Lee, S. Bakkannagari, N. G. Ordonez, W. K. Hong, I. Wistuba, and F. M. Johnson
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion
Mol. Cancer Ther., July 1, 2007; 6(7): 1962 - 1972.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Yamasaki, M. J. Johansen, D. Zhang, S. Krishnamurthy, E. Felix, C. Bartholomeusz, R. J. Aguilar, K. Kurisu, G. B. Mills, G. N. Hortobagyi, et al.
Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Down-regulation of MMAC1/PTEN and Up-regulation of Phosphorylated Akt
Cancer Res., June 15, 2007; 67(12): 5779 - 5788.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
E. T. Olejniczak, C. Van Sant, M. G. Anderson, G. Wang, S. K. Tahir, G. Sauter, R. Lesniewski, and D. Semizarov
Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains
Mol. Cancer Res., April 1, 2007; 5(4): 331 - 339.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. M. Stadler
The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents
Mol. Cancer Ther., April 1, 2007; 6(4): 1180 - 1185.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
L. Daniele, L. Macri, M. Schena, D. Dongiovanni, L. Bonello, E. Armando, L. Ciuffreda, O. Bertetto, G. Bussolati, and A. Sapino
Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens
Mol. Cancer Ther., April 1, 2007; 6(4): 1223 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. V. Sequist
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Oncologist, March 1, 2007; 12(3): 325 - 330.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. V. Sequist, D. W. Bell, T. J. Lynch, and D. A. Haber
Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non-Small-Cell Lung Cancer
J. Clin. Oncol., February 10, 2007; 25(5): 587 - 595.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Fichera, N. Little, S. Jagadeeswaran, U. Dougherty, A. Sehdev, R. Mustafi, S. Cerda, W. Yuan, S. Khare, M. Tretiakova, et al.
Epidermal Growth Factor Receptor Signaling Is Required for Microadenoma Formation in the Mouse Azoxymethane Model of Colonic Carcinogenesis
Cancer Res., January 15, 2007; 67(2): 827 - 835.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
Y. Yan, Y. Lu, M. Wang, H. Vikis, R. Yao, Y. Wang, R. A. Lubet, and M. You
Effect of an Epidermal Growth Factor Receptor Inhibitor in Mouse Models of Lung Cancer
Mol. Cancer Res., December 1, 2006; 4(12): 971 - 981.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
H. E Jones, J. M W Gee, I. R Hutcheson, J. M Knowlden, D. Barrow, and R. I Nicholson
Growth factor receptor interplay and resistance in cancer
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S45 - S51.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
I. R Hutcheson, J. M Knowlden, H. E Jones, R. S Burmi, R. A McClelland, D. Barrow, J. M W Gee, and R. I Nicholson
Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S89 - S97.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
Y. Ishii, S. Fujimoto, and T. Fukuda
Gefitinib Prevents Bleomycin-induced Lung Fibrosis in Mice
Am. J. Respir. Crit. Care Med., September 1, 2006; 174(5): 550 - 556.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Dimitroulakos, I. A. Lorimer, and G. Goss
Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway.
Clin. Cancer Res., July 15, 2006; 12(14): 4426s - 4431s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. H. Johnson
Targeted therapies in combination with chemotherapy in non-small cell lung cancer.
Clin. Cancer Res., July 15, 2006; 12(14): 4451s - 4457s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Ho, G. Bebb, and N. Murray
In Reply
J. Clin. Oncol., July 1, 2006; 24(19): 3214 - 3215.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
E. E. W. Cohen, M. W. Lingen, B. Zhu, H. Zhu, M. W. Straza, C. Pierce, L. E. Martin, and M. R. Rosner
Protein Kinase C{zeta} Mediates Epidermal Growth Factor-Induced Growth of Head and Neck Tumor Cells by Regulating Mitogen-Activated Protein Kinase.
Cancer Res., June 15, 2006; 66(12): 6296 - 6303.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Ando, I. Okamoto, N. Yamamoto, K. Takeda, K. Tamura, T. Seto, Y. Ariyoshi, and M. Fukuoka
Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib
J. Clin. Oncol., June 1, 2006; 24(16): 2549 - 2556.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Cohen, R. Mustafi, A. Chumsangsri, N. Little, J. Nathanson, S. Cerda, S. Jagadeeswaran, U. Dougherty, L. Joseph, J. Hart, et al.
Epidermal Growth Factor Receptor Signaling Is Up-regulated in Human Colonic Aberrant Crypt Foci
Cancer Res., June 1, 2006; 66(11): 5656 - 5664.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Van Schaeybroeck, J. Kyula, D. M. Kelly, A. Karaiskou-McCaul, S. A. Stokesberry, E. Van Cutsem, D. B. Longley, and P. G. Johnston
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells
Mol. Cancer Ther., May 1, 2006; 5(5): 1154 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Nicolle, A. Daher, P. Maille, M. Vermey, S. Loric, A. Bakkar, H. Wallerand, D. Vordos, F. Vacherot, S. G. D. de Medina, et al.
Gefitinib Inhibits the Growth and Invasion of Urothelial Carcinoma Cell Lines in which Akt and MAPK Activation Is Dependent on Constitutive Epidermal Growth Factor Receptor Activation.
Clin. Cancer Res., May 1, 2006; 12(9): 2937 - 2943.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Janmaat, M. I. Gallegos-Ruiz, J. A. Rodriguez, G. A. Meijer, W. L. Vervenne, D. J. Richel, C. Van Groeningen, and G. Giaccone
Predictive Factors for Outcome in a Phase II Study of Gefitinib in Second-Line Treatment of Advanced Esophageal Cancer Patients
J. Clin. Oncol., April 1, 2006; 24(10): 1612 - 1619.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. Sakaguchi, Y. Kuroda, and M. Hirose
The antiproliferative effect of lidocaine on human tongue cancer cells with inhibition of the activity of epidermal growth factor receptor.
Anesth. Analg., April 1, 2006; 102(4): 1103 - 1107.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
A. Angelucci, G. L. Gravina, N. Rucci, D. Millimaggi, C. Festuccia, P. Muzi, A. Teti, C. Vicentini, and M. Bologna
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 197 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Sato, M. B. Vaughan, L. Girard, M. Peyton, W. Lee, D. S. Shames, R. D. Ramirez, N. Sunaga, A. F. Gazdar, J. W. Shay, et al.
Multiple Oncogenic Changes (K-RASV12, p53 Knockdown, Mutant EGFRs, p16 Bypass, Telomerase) Are Not Sufficient to Confer a Full Malignant Phenotype on Human Bronchial Epithelial Cells
Cancer Res., February 15, 2006; 66(4): 2116 - 2128.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Xue, J. Wyckoff, F. Liang, M. Sidani, S. Violini, K.-L. Tsai, Z.-Y. Zhang, E. Sahai, J. Condeelis, and J. E. Segall
Epidermal Growth Factor Receptor Overexpression Results in Increased Tumor Cell Motility In vivo Coordinately with Enhanced Intravasation and Metastasis
Cancer Res., January 1, 2006; 66(1): 192 - 197.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. L. Rothenberg, B. LaFleur, D. E. Levy, M. K. Washington, S. L. Morgan-Meadows, R. K. Ramanathan, J. D. Berlin, A. B. Benson III, and R. J. Coffey
Randomized Phase II Trial of the Clinical and Biological Effects of Two Dose Levels of Gefitinib in Patients With Recurrent Colorectal Adenocarcinoma
J. Clin. Oncol., December 20, 2005; 23(36): 9265 - 9274.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Gasparini, R. Sarmiento, S. Amici, R. Longo, D. Gattuso, M. Zancan, and M. Gion
Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate
Ann. Onc., December 1, 2005; 16(12): 1867 - 1873.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Kassouf, C. P.N. Dinney, G. Brown, D. J. McConkey, A. J. Diehl, M. Bar-Eli, and L. Adam
Uncoupling between Epidermal Growth Factor Receptor and Downstream Signals Defines Resistance to the Antiproliferative Effect of Gefitinib in Bladder Cancer Cells
Cancer Res., November 15, 2005; 65(22): 10524 - 10535.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Ho, J. E. Minturn, T. Hishiki, H. Zhao, Q. Wang, A. Cnaan, J. Maris, A. E. Evans, and G. M. Brodeur
Proliferation of Human Neuroblastomas Mediated by the Epidermal Growth Factor Receptor
Cancer Res., November 1, 2005; 65(21): 9868 - 9875.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. W. Bell, T. J. Lynch, S. M. Haserlat, P. L. Harris, R. A. Okimoto, B. W. Brannigan, D. C. Sgroi, B. Muir, M. J. Riemenschneider, R. B. Iacona, et al.
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non-Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
J. Clin. Oncol., November 1, 2005; 23(31): 8081 - 8092.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Ishikawa, Y. Daigo, A. Takano, M. Taniwaki, T. Kato, S. Hayama, H. Murakami, Y. Takeshima, K. Inai, H. Nishimura, et al.
Increases of Amphiregulin and Transforming Growth Factor-{alpha} in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non-Small Cell Lung Cancers
Cancer Res., October 15, 2005; 65(20): 9176 - 9184.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Van Schaeybroeck, A. Karaiskou-McCaul, D. Kelly, D. Longley, L. Galligan, E. Van Cutsem, and P. Johnston
Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy
Clin. Cancer Res., October 15, 2005; 11(20): 7480 - 7489.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Stegmaier, S. M. Corsello, K. N. Ross, J. S. Wong, D. J. DeAngelo, and T. R. Golub
Gefitinib induces myeloid differentiation of acute myeloid leukemia
Blood, October 15, 2005; 106(8): 2841 - 2848.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
A. R Gunthert, C. Grundker, A. Olota, J. Lasche, N. Eicke, and G. Emons
Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen
Eur. J. Endocrinol., October 1, 2005; 153(4): 613 - 625.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. M. Johnson, B. Saigal, M. Talpaz, and N. J. Donato
Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non-Small Cell Lung Cancer Cells
Clin. Cancer Res., October 1, 2005; 11(19): 6924 - 6932.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. C. Daw, W. L. Furman, C. F. Stewart, L. C. Iacono, M. Krailo, M. L. Bernstein, J. E. Dancey, R. A. Speights, S. M. Blaney, J. M. Croop, et al.
Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children's Oncology Group Study
J. Clin. Oncol., September 1, 2005; 23(25): 6172 - 6180.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. Solomon, D. Binns, P. Roselt, L. I. Weibe, G. A. McArthur, C. Cullinane, and R. J. Hicks
Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging
Mol. Cancer Ther., September 1, 2005; 4(9): 1417 - 1422.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. S. Siegel-Lakhai, J. H. Beijnen, and J. H.M. Schellens
Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva(R)) and Gefitinib (Iressa(R))
Oncologist, September 1, 2005; 10(8): 579 - 589.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Jain, C. A. Tindell, I. Laux, J. B. Hunter, J. Curran, A. Galkin, D. E. Afar, N. Aronson, S. Shak, R. B. Natale, et al.
Epithelial membrane protein-1 is a biomarker of gefitinib resistance
PNAS, August 16, 2005; 102(33): 11858 - 11863.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Taron, Y. Ichinose, R. Rosell, T. Mok, B. Massuti, L. Zamora, J. L. Mate, C. Manegold, M. Ono, C. Queralt, et al.
Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas
Clin. Cancer Res., August 15, 2005; 11(16): 5878 - 5885.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga, J. Albanell, A. Ruiz, A. Lluch, P. Gascon, V. Guillem, S. Gonzalez, S. Sauleda, I. Marimon, J. M. Tabernero, et al.
Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
J. Clin. Oncol., August 10, 2005; 23(23): 5323 - 5333.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-H. Yang, C.-J. Huang, C.-S. Yang, Y.-C. Chu, A.-L. Cheng, J. Whang-Peng, and P.-C. Yang
Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein
Cancer Res., August 1, 2005; 65(15): 6943 - 6949.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Schilder, M. W. Sill, X. Chen, K. M. Darcy, S. L. Decesare, G. Lewandowski, R. B. Lee, C. A. Arciero, H. Wu, and A. K. Godwin
Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study
Clin. Cancer Res., August 1, 2005; 11(15): 5539 - 5548.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Kiguchi, L. Ruffino, T. Kawamoto, T. Ajiki, and J. DiGiovanni
Chemopreventive and Therapeutic Efficacy of Orally Active Tyrosine Kinase Inhibitors in a Transgenic Mouse Model of Gallbladder Carcinoma
Clin. Cancer Res., August 1, 2005; 11(15): 5572 - 5580.
[Abstract] [Full Text]